A multiethnic, prospective cohort study involving 600 women with Stage I–IIIA BC found that high serum levels of IGF-1 and the IGF-1/IGFBP-3 ratio were associated with a higher risk of all-cause mortality. The gene discussed is IGFBP3; the disease is breast cancer.